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Abstract
Objectives
HPV infection causes cervical cancer, yet information on prevalence and risk factors for
HPV in Africa remain sparse. This study describes the prevalence of HPV genotypes and
risk factors associated with HPV among young women 30 years of age in KwaZulu-Natal
(KZN), South Africa.
Methods
Cervicovaginal lavage samples were tested for HPV genotypes in 224 women enrolled in a
prospective cohort study. Clinical, behavioural and demographic data were collected. We
measured prevalence of HPV genotypes and using logistic regression, examined for factors
associated with HPV.
Results
Median age of participants was 21 years [interquartile range (IQR):18–23]. The overall prev-
alence of HPV was 76.3% (171/224) with multiple and single genotypes prevalent in 56.3%
and 20.1% of women respectively. Proportion of women with high-risk genotypes (16, 18,
31, 33, 35, 39, 45, 51, 52, 56 and 58) was 54.5%. Women not living with their partner
[adjusted odds ratio (aOR)] = 3.42 95% CI1.22–9.60; p = 0.019), was significantly associ-
ated with HPV infection and high-risk HPV genotype infection.
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Conclusion
The high burden of HPV and associated risk behaviours highlight the need to intensify
behavioural interventions to prevent HPV acquisition in young women. The large scale
delivery of HPV vaccine should be prioritised to prevent HPV acquisition and reduce HPV-
related morbidity.
Introduction
Human papillomavirus (HPV) is one of the most prevalent sexually transmitted viruses [1, 2].
More than 100 types of HPV have been identified, and of these about 40 types are known to
infect the anogenital tract. Eighteen types; in particular, HPV 16 and HPV 18, described as
high-risk/oncogenic types, are associated with the development of cervical cancer. The low-
risk/non-oncogenic HPV types (mainly types 6 and 11), result in genital warts [2]. The major-
ity of cervical HPV infections are cleared or suppressed by cell-mediated immunity within 1–2
years of exposure [3]. Persistent cervical HPV infection with high- risk/oncogenic types is asso-
ciated with an increased risk of cervical intraepithelial neoplasia (CIN) and eventual malig-
nancy [3]. Additionally, HPV is associated with non-cervical cancers such as vulval, vaginal,
anal and oropharyngeal cancers [4].
Globally, the prevalence of HPV among women with normal cytology is around 12%, whilst
in Sub-Saharan Africa the rates are much higher at around 24%, ranging from 17.4% to 33.6%
[5]. Young women<25 years of age remain disproportionately affected with HPV prevalence
of 19.2% globally, reaching a high of 43.9% in Africa in this age group [5]. Amongst women
with cervical pathology, prevalence increases in proportion to the severity of lesions and
reaches around 99% in women with cervical cancer, contributing to significant morbidity and
mortality [1, 4]. Although risk factors for HPV acquisition have been difficult to assess these
include risky sexual behaviours, particularly early sexual debut, multiple sex partners, lack of
condom use, early pregnancy and hormonal contraceptive (HC) use [6]. Thus, primary preven-
tion through education and promotion of safe sexual practices remains key to reducing HPV
acquisition.
The recently developed HPV vaccines offer hope in reducing HPV acquisition, a necessary
cause in the pathogenesis of cervical cancer. Two types of vaccines are currently available in
South Africa: a bivalent vaccine targeting genotypes 16 and 18 and a quadrivalent vaccine tar-
geting genotypes 6/11/16/18 [7]. The randomized controlled trials as well as a systematic
review and meta-analysis, have demonstrated the efficacy of HPV vaccines for the primary pre-
vention of HPV-related cervical malignancies and anogenital warts [8, 9]. The target popula-
tion for vaccination includes young girls before the average age of sexual debut [10]. This age is
determined by country-specific data on the mean age of sexual debut for girls, and includes in
most instances girls<15 years old [10]. In South Africa, girls aged 9–12 years have been priori-
tised to receive the HPV vaccine [7] and recent data suggests (N = 963), that the overall uptake
of the quadrivalent vaccine was high and it was 99.7%, 97.9% and 97.8% for the first, second
and third doses respectively; with no adverse events attributable to the HPV vaccine [7].
In this study we determined the prevalence of HPV genotypes and explored the socio-
demographic and behavioural factors associated with prevalent HPV among young women in
KZN, South Africa.
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Methods
Study Population and Sample Collection
This study was an ancillary study nested within a larger HIV seroincidence study conducted by
the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in rural and
urban KZN fromMarch 2004 to May 2007 [11]. Briefly, following informed consent, sexually
active HIV-negative women aged 14–30 years attending public sector primary health care clin-
ics for family planning services and management of sexually transmitted infections were
enrolled. Nurse-administered interviews with structured questionnaires were used to collect
demographic, clinical, reproductive and sexual behavioural data at baseline and at each
monthly follow-up visit. At enrolment, and at each quarterly and at the study exit visit all
women underwent physical and clinical examinations. Blood and cervicovaginal lavage (CVL)
samples were collected for study related primary and secondary endpoints [11]. Of the 594
women enrolled, we tested CVL samples from 224 women for HPV genotypes at one time
point prior to HIV seroconversion. Of the 224 women, 110 had results available for more than
one time point. Participants were evaluated as HPV positive or negative depending on results
of CVL genotype testing. Regarding evaluation of HPV types, all types that were detected per
participant were enumerated irrespective of the time points they were obtained at. High-risk
genotypes [1] were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58. The first measured HPV typing
data was at a median of 6.4 months (IQR 5.6–17.9) post-enrolment. The baseline characteris-
tics of the 370 women not included for HPV testing did not differ significantly from those of
the remaining women [11]. Participant identifying information was removed prior to testing
and analysis. The Institutional Review Board (IRB) at Columbia University, New York
approved the nested study (Reference number IRB-AAAM1102) based on study participants
providing informed consent in the parent study which had been approved by the University of
KwaZulu-Natal Biomedical Research Ethics Committee (Reference number E197/03). This
study was also approved by the Research Ethics Committee of the University of Cape Town
(Reference number 459/2011).
Laboratory Testing
The Roche Linear Array HPV Genotyping Test (Roche Diagnostics, Mannheim, Germany)
was used for the detection of 37 high- and low-risk HPV genotypes in specimens. DNA from
cervico-vaginal lavage (CVL) cell pellet was extracted for HPV typing using the Magna Pure
Compact Nucleic Acid Isolation Kit I (Roche Diagnostics, Mannheim, Germany). This kit was
used in conjunction with the MagNA Pure Compact Instrument (Roche Diagnostics, Mann-
heim, Germany) employing an automated extraction procedure performed according to the
manufacturer’s instruction. Samples were tested blinded of other demographic, behavioural
and HIV infection status data.
Statistical Analyses
Baseline variables were summarized as percentages for categorical variables, and mean or
median for continuous variables [11]. Although a prospective cohort study was conducted,
HPV genotyping data were available for 51% (114/224) of participants at only one time-point,
thus logistic regression was performed to evaluate the association between baseline variables
and prevalent HPV. Unordered polytomous regression techniques were used to test the associ-
ations between the baseline variables and HPV risk type (high-risk or low-risk HPV). Each
baseline characteristic variable was adjusted for against the other variables in the model. Data
were analysed with SAS statistical package version 9.3 (SAS Institute, Inc., Cary).
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Results
Demographic characteristics
All 224 enrolled women were Black African with a median age of 21 years (interquartile range
[IQR]: 18–23 years). Just over half (n = 129; 57.6%) of the women were from the rural area.
Majority (n = 204; 91.5%) of the women were in a relationship and reported having had one
sex partner (n = 203; 91.0%). Whilst a third (n = 70; 31.7%) reported use of an injectable HC,
about a quarter (n = 60; 27.1%) reported using depot medroxyprogesterone acetate (DMPA) or
norethisterone enantate (Nuristerate) (n = 10; 4.5%). Less than half of the women (n = 104;
47.1%) reported condom use (Table 1).
HPV prevalence and genotype distribution
HPV prevalence was 76.3% (171/224) [95% confidence interval (CI) 70.8%-81.9%]. The distri-
bution of the genotypes is shown in S1 Fig. Multiple concurrent and single HPV genotypes
were prevalent in 56.3% (126/224) and 20.1% (45/224) of women respectively. The distribution
of multiple concurrent infections (Range: 2–12 HPV genotypes) is shown in S2 Fig. Among
women under 18 years of age, 54.1% (20/37) had multiple concurrent HPV genotypes detected,
whilst prevalence of multiple concurrent infections among women18 years old was 77.4%
(106/137). High-risk genotypes (1) of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56 and 58 were present
in 78.6% (99/126) of women with multiple concurrent and 51.1% (23/45) of women with single
genotype infections. Overall the proportion of women with these high-risk genotypes was
54.5% (122/224). Among women with HPV infection, prevalence of high-risk genotypes was
71.3% (122/171). Regarding the number of participants infected with high-risk genotypes; the
proportion infected with the vaccine genotypes (16±18) was 21% (47/224). In our sample, we
did not find that any combinations of HPV types that were more common together.
Risk factors for HPV
HPV was significantly associated in women who were not living with their partner (adjusted
odds ratio (aOR) = 3.42; 95% CI 1.22–9.60; p = 0.019) (Table 1). Results did not reach statistical
significance for the other demographic/behavioural characteristics described next. The odds
for HPV were higher in women from an urban compared to a rural setting (aOR = 1.87; 95%
CI 0.81–4.33; p = 0.144) and in those practicing intra-vaginal substance use of water with salt,
vinegar, soap or douching with antiseptics containing parachlorometaxylenol or povidone
iodine products or traditional herbs for personal hygiene before or after sex (aOR = 1.98; 95%
CI 0.88–4.49; p = 0.099). Among women having more than one partner in the last 3 months,
the odds of HPV was higher (aOR = 2.00; 95% CI 0.41–9.89; p = 0.393). These findings were
similar among women with a partner (either married or not) (aOR = 2.08; 95% CI 0.68–6.32;
p = 0.198). Neither injectable contraception use nor condom use were associated with prevalent
HPV.
Among women not living with their partner, 56% (112/200) had high-risk HPV infection.
These women also had higher odds of having high-risk HPV infection compared to being HPV
negative (aOR = 4.08; 95% CI 1.34–12.41; p = 0.013). Similarly, women who practiced intra-
vaginal substance use had 2-fold higher odds of high-risk HPV infection (aOR = 2.33; 95% CI
1.01–5.39; p = 0.049). The distribution of high-risk HPV infection in these women was 66.7%
(48/72). There were no observed associations between baseline risk factors and particular
genotypes.
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Table 1. Baseline characteristics associated with prevalent HPV infection in young women in KwaZulu-Natal, South Africa (N = 224).
Unadjusted analysis Adjusted analysis
Baseline Characteristic Distribution % (n) HPV infection % (n) Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value
Age group (years)
<18 16.5% (37) 70.3% (26) 1.0 1.0
18 83.5% (187) 77.5% (145) 1.46 (0.67–3.20) 0.344 1.28 (0.50–3.25) 0.607
Site
Rural 57.6% (129) 70.5% (91) 1.0 1.0
Urban 42.4% (95) 84.2% (80) 2.23 (1.14–4.35) 0.019 1.87 (0.81–4.33) 0.144
Relationship statusa*
Single/no partner 8.5% (19) 63.2% (12) 1.0 1.0
With partner 91.5% (204) 77.9% (159) 2.06 (0.77–5.54) 0.152 2.08 (0.68–6.32) 0.198
Partner has other
partners
No 22.3% (50) 70.0% (35) 1.0 1.0
Yes 25.5% (57) 75.4% (43) 1.32 (0.56–3.09) 0.528 1.12 (0.44–2.84) 0.807
Don’t Know 52.2% (117) 79.5% (93) 1.66 (0.78–3.53) 0.187 1.46 (0.64–3.31) 0.364
Living with partner
Yes 10.7% (24) 62.5% (15) 1.0 1.0
No 89.3% (200) 78.0% (156) 2.12 (0.87–5.19) 0.100 3.42 (1.22–9.60) 0.019
Number of sexual partners in the last 3
monthsa
1 partner 91.0% (203) 74.9% (152) 1.0 1.0
2 partners 9.0% (20) 90.0% (18) 3.02(0.68–13.46) 0.147 2.00 (0.41–9.89) 0.393
Vaginal insertion
practices
No 67.9% (152) 72.4% (110) 1.0 1.0
Yes 32.1% (72) 84.7% (61) 2.12 (1.02–4.41) 0.045 1.98 (0.88–4.48) 0.099
Injectable contraceptive useb
No 68.3% (151) 78.8% (119) 1.0 1.0
Yes 31.7% (70) 71.4% (50) 0.67 (0.35–1.29) 0.231 0.79 (0.438–1.60) 0.482
Injectable contraceptive typeb
None 68.3% (151) 78.8% (119) 1.0
Nuristeratec 4.6% (10) 80.0% (8) 1.08 (0.22–5.32) 0.929
DMPAd 27.1% (60) 69.5% (41) 0.61 (0.31–1.21) 0.156
Condom useb
Yes 47.1% (104) 79.8% (83) 1.0 1.0
No 52.9% (117) 73.5% (86) 0.70 (0.37–1.32) 0.271 0.68 (0.34–1.37) 0.283
Abnormal pelvic exam
No 58.0% (130) 73.1% (95) 1.0 1.0
Yes 42.0% (94) 80.9% (76) 1.56 (0.82–2.96) 0.178 1.43 (0.71–2.89) 0.317
Data missing for
a one, and
b three women
c norethisterone enantate
d depot medroxyprogesterone acetate
* With partner category includes married and unmarried women
doi:10.1371/journal.pone.0146603.t001
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Discussion
The overall HPV prevalence of 76.3% in our study is almost 3–4 fold higher than reported esti-
mates [12], demonstrating the high burden amongst both urban and rural women. Importantly
this is the first study in South Africa that determined the prevalence of HPV in a rural setting
(70.5%).
The prevalence of high-risk genotypes in this study was 54.5%. In a recent study of 1,472
women from the Gauteng province, the prevalence of HPV DNA was 74.6% with high- risk
HPV DNA in 54.3% [12]; similar to the 56.3% in this study. A large cohort study describing
the prevalence and distribution of HPV genotypes among women in Cape Town, South Africa,
showed an overall prevalence of HPV DNA of 25.4% (2,389/9,429). One or more high-risk
HPV genotypes were present in 78.5% (1,848/2,354) of women, which is considerably higher
than that reported in our study [13]. This may be due to the fact that this study looked at the
distribution of HPV genotypes among both HIV-positive and HIV-negative women.
Women 18 years and older had a higher likelihood of multiple HPV genotype infection in
this study. This may be due to a biological mechanism by which the acquisition of one geno-
type of HPV does, in some way, facilitate acquisition of another genotype [14]. Also, sexual
behaviour (frequency of intercourse, number of sex partners) or sex partner characteristics
(number of HPV types in the partner/s) are important risk factors for multiple HPV genotype
infection [14].There is no consensus in the literature regarding the importance of multiple con-
current infections. It is well established that increased duration of infection (persistence) with
high risk HPV genotypes is associated with a concomitant increased risk of cervical dysplasia
[15]. Furthermore, multiple concurrent infections may be associated with HPV persistence,
hence an increased risk of cervical disease compared to single infection [16]; however this has
not been consistently demonstrated [17, 18].
Epidemiological data on HPV prevalence and type distribution is crucial to evaluate the
future impact of HPV vaccines. In this study, the number of women infected with vaccine
high-risk genotypes was modest at 21% and is in keeping with findings from a cohort of sexu-
ally active HIV-uninfected South African adolescents (15.4%) [15]. Some authors have
expressed concern that currently available HPV vaccines, even with wide coverage, may not
prevent infection with the majority of high-risk HPV genotypes [15]. However, studies have
shown that both the bivalent and quadrivalent vaccines show evidence of cross-protection
against non-vaccine high-risk HPV genotypes [predominantly HPV 31, 33, 35 and 45] [8, 19].
This is due to the high homology of some HPV genotypes with vaccine genotypes: HPV 31/35
are closely related to HPV 16; whilst HPV 45 is more closely related to HPV 18 [19]. A nonava-
lent vaccine, containing virus-like-particles (VLPs) of 9 high-risk HPV genotypes (6, 11, 16, 18,
31, 33, 45, 52, and 58) currently in phase III trials, may provide broader protection against the
HPV genotypes associated with cervical cancer [20].
In our study we found that HPV prevalence was high both among women<18 years
(70.3%) and18 years (77.5%) old. These results are higher compared to global and local
trends [5, 21] and explain that most HPV infections occur soon after initiation of sexual activ-
ity, highlighting the burden of HPV at a very young age and the potential future risk of invasive
cervical disease, as well as the importance of targeting young girls aged 9–12 years (in our set-
ting) for HPV vaccination [7]. It is also important to mention that in South Africa, HIV preva-
lence amongst young women compared to young men is at least 5-fold higher and young
women in the age group 15 to 24 years remain the worst affected [22]. Thus, over time, women
receiving antiretroviral therapy will survive longer making it a priority to screen for cervical
cancer in this population due to their high burden of HPV infection.
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Women reported to be with a partner yet not living with their partners, were at a 3.5 times
greater risk of HPV infection, and had a similar risk of having high-risk HPV infection; sug-
gesting that unmeasured sexual behaviour and sex partner characteristics (frequency of inter-
course, cumulative number of sex partners, number of previous/current partners of sex
partners or number of HPV genotypes in the sex partner/s) were important risk factors [14].
Thus larger studies evaluating these sexual behaviour correlates are needed to better explain
this association; being cognisant of cultural marriage practices and issues such as reporting
biases of sensitive behaviours in face-to-face interviews.
Regarding the role of HC use, HPV acquisition and subsequent development of cervical
cancer; findings have been inconsistent as reported in the review by Morrison et al [23] where
an early study showed an increased risk [24], whilst a later study showed a non-significant pro-
tective effect [25]. Another study showed no association between HC use and high-risk HPV
infection or on high-grade CIN and disease progression [26]. In this study we did not find an
association with HC use and HPV, though genital tract alteration is known to be associated
with HC use having greater likelihood of cervical ectopy and thinning of the cervico-vaginal
epithelium predisposing to HPV acquisition [23]. Furthermore, HC use is linked to sexual risk
behaviours, thus sexual behaviour correlates, together with better measures of HC use, must be
taken into account in order to determine the true effect of HC use on HPV acquisition.
Intravaginal practices may be associated with risk of HPV infection due to alterations in the
vaginal pH, microflora, or cervical mucous [27]. In this study, vaginal insertion practices were
significantly associated with high-risk HPV infection. These findings are in keeping with a
study among adolescent females in the United States which showed that vaginal douching dur-
ing the last 90 days was associated with HPV infection (OR = 2.1, 95% CI 1.2–3.6) [27]. How-
ever, findings from a South African study did not show increased risk of HPV infection among
participants who reported vaginal insertion practices [28]. Conflicting results in the literature
may be due to inherent biases of self-reported sexual behaviour correlates, differing practices
and types of products used.
There are several limitations in our study. It is a small sample with limited power. We did
not find an association with behavioural measures and condom use and prevalent HPV; reli-
able measurement of behaviours including consistent condom use remains problematic since
face-to-face interviews were conducted leading to reporting bias due to social desirability (per-
haps an over reporting of condom use) that could attenuate any true analysis of the effect of
condoms [29]. The effectiveness of condom use in reducing HPV acquisition has not been
proven, but the trend is towards a protective effect [29, 30]. However a paradoxical effect has
also been reported; that is condom use is associated with an increased risk of HPV acquisition
probably due to the fact that women may be more likely to use a condom if they feel they are at
high risk of sexually transmitted infection (STI) transmission from a partner [31]. Further-
more, the small sample size may have precluded any meaningful interpretation of the associa-
tion between risk factors and particular genotypes; as well as the detection of any combinations
of HPV types that were more common together.
Our small sample size and the target population of Black African women aged 14–30 years
limits generalizability to all women in South Africa, including women outside sub-Saharan
Africa. Nevertheless, our population represented young sexually active women at risk of
acquiring infections that are sexually transmitted. Whilst we used a molecular method for
genotype identification, testing was carried out on stored samples and it is possible that there
could be over time, some deterioration of sample quality with HPV positive samples misclassi-
fied as false-negative. Despite this misclassification HPV prevalence was as high and similar to
reports from this region.
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Conclusion
The prevalence of HPV among women<18 years of age was extraordinarily high and it is
therefore imperative that there should be determined efforts to rapidly roll-out, scale up and
maximize on coverage of the recently developed highly effective HPV vaccines in preventing
HPV acquisition, crucial to decreasing morbidity and mortality [32].
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